| Old Articles: <Older 2361-2370 Newer> |
|---|
 |
The Motley Fool
September 9, 2005
Stephen D. Simpson |
Diabetics Breathing Easier Investors in Pfizer, Sanofi-Aventis, and Nektar Therapeutics might be breathing a bit easier today. The FDA's expert panel recommended approval for Exubera.   |
BusinessWeek
September 19, 2005
Gene G. Marcial |
AMN To The Rescue In the wake of the Katrina catastrophe, demand for health-care services to alleviate the suffering has exploded. One company that will help fill the gap, says a stock analyst, is AMN Healthcare Services, the largest national supplier of temporary nurses. |
The Motley Fool
September 8, 2005
Stephen D. Simpson |
Raising the Barr This large generics company sees better margins and an optimistic outlook. The company has a top-notch return on assets and a valuation that, while not cheap, isn't ridiculous either. |
The Motley Fool
September 7, 2005
Stephen D. Simpson |
Smashing Good Deal, Eh? Glaxo's purchase of Canadian ID Biomedical will seriously augment its vaccine capabilities. Investors, take note. |
The Motley Fool
September 7, 2005
Stephen D. Simpson |
The Little Lab That Could Bio-Reference is a small business with big potential. The company has an appealing cancer and genomics business (GenPath). For investors seeking successful yet unknown companies, this one is worth watching. |
The Motley Fool
September 7, 2005
Rich Duprey |
Is Chiron Worth It? The vaccine maker rejects Novartis' bid of $40 a share as inadequate. How much should the pharma pay? Investors, take note. |
Fast Company
September 2005
Jennifer Reingold |
CEO See-Ya! David Mott, CEO of Medimmune Inc. is compensated with millions while the company's stock suffers. |
The Motley Fool
September 6, 2005
W.D. Crotty |
An Anxious Time for Andrx Questions about its manufacturing lead the FDA to take action. The generic drug company's stock was the largest percentage loser on the Nasdaq this morning. |
The Motley Fool
September 6, 2005
Stephen D. Simpson |
FDA's Eye on 2 Potential Blockbusters This week, FDA advisory panels will consider the marketing approval applications of Exubera, the inhaled insulin from Pfizer/Sanofi/Nektar, and Pargluva, the dual PPAR agonist, taken in pill form, from Bristol-Myers and Merck. Investors, take note. |
The Motley Fool
September 6, 2005
Rich Duprey |
Flamel's Dubious Future French nanotech pioneer loses deal with TAP Pharmaceuticals for heartburn formulation. There's just too much fog facing this company for investors to see clearly ahead. |
| <Older 2361-2370 Newer> Return to current articles. |
